Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
330 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05429632 | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT(MO-TRANS) | recruiting | Phase 3 | 366 | Priothera SASINDUSTRY | 14 | Jul 17, 2026 | clinicaltrials |
| NCT05592938 | Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)(PRESERVE) | recruiting | N/A | 171 | University Health Network, TorontoOTHER | 10 | Jul 17, 2026 |
| clinicaltrials |
| NCT06788990 | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC(FORTIFI-HN01) | recruiting | Phase 2 / Phase 3 | 650 | Bicara TherapeuticsINDUSTRY | 26 | Jul 17, 2026 | clinicaltrials |
| NCT07707648 | Evaluation of the Feasibility and Safety of ENCER for Cancer Treatment-Related Fatigue in Patients Receiving Chemotherapy or Radiotherapy(CTRF) | recruiting | Early Phase 1 | 74 | Beaura for Para Pharmaceutical Products Trading LLCOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06615635 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients(DaRT) | recruiting | N/A | 28 | Alpha Tau Medical LTD.INDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
| NCT05650632 | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 210 | AbbVieINDUSTRY | 7 | Jul 13, 2026 | clinicaltrials |
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia(Interfant-21) | recruiting | Phase 3 | 160 | Princess Maxima Center for Pediatric OncologyOTHER | 24 | Jul 10, 2026 | clinicaltrials |
| NCT05137054 | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | recruiting | Phase 1 | 317 | Regeneron PharmaceuticalsINDUSTRY | 5 | Jul 8, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT04184973 | Efficacy and Safety of the CG-100 Intraluminal Bypass Device | recruiting | N/A | 250 | Colospan Ltd.INDUSTRY | 5 | Jul 6, 2026 | clinicaltrials |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01) | recruiting | Phase 3 | 582 | Daiichi SankyoINDUSTRY | 25 | Jul 2, 2026 | clinicaltrials |
| NCT04064060 | A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | recruiting | Phase 3 | 665 | CelgeneINDUSTRY | 22 | Jul 1, 2026 | clinicaltrials |
| NCT07049276 | The Multicentre Selective Lymphadenectomy Trial - 3(MSLT-3) | recruiting | N/A | 1,500 | Melanoma Institute AustraliaOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT05009992 | Combination Therapy for the Treatment of Diffuse Midline Gliomas(PNOC022) | recruiting | Phase 2 | 360 | University of California, San FranciscoOTHER | 6 | Jun 26, 2026 | clinicaltrials |
| NCT06216301 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC(LUNAR-2) | recruiting | Phase 3 | 734 | NovoCure GmbHINDUSTRY | 16 | Jun 25, 2026 | clinicaltrials |
| NCT04641247 | A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | recruiting | Phase 2 | 37 | GlaxoSmithKlineINDUSTRY | 8 | Jun 24, 2026 | clinicaltrials |
| NCT05584670 | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | SanofiINDUSTRY | 6 | Jun 23, 2026 | clinicaltrials |
| NCT07636252 | Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma | recruiting | — | 400 | Sheba Medical CenterOTHER_GOV | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05696626 | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation(ELAINEIII) | recruiting | Phase 3 | 600 | LeonaBioINDUSTRY | 17 | Jun 22, 2026 | clinicaltrials |
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | recruiting | Phase 3 | 400 | Ascentage Pharma Group Inc.INDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT04534127 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia | recruiting | N/A | 56 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04643002 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | recruiting | Phase 1 / Phase 2 | 258 | SanofiINDUSTRY | 10 | Jun 16, 2026 | clinicaltrials |
| NCT05632913 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer | recruiting | N/A | 10 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05657743 | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety) | recruiting | N/A | 15 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05781555 | Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors | recruiting | N/A | 100 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06202248 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer. | recruiting | N/A | 10 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07646171 | EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)(MBC) | recruiting | — | 19 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04777994 | Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors | recruiting | Phase 1 | 248 | Calico Life Sciences LLCINDUSTRY | 6 | Jun 4, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT05890677 | The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema(LYMPH) | recruiting | N/A | 280 | University Hospital, Basel, SwitzerlandOTHER | 15 | Jun 4, 2026 | clinicaltrials |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma(JADE) | recruiting | Phase 3 | 864 | GlaxoSmithKlineINDUSTRY | 31 | May 26, 2026 | clinicaltrials |
| NCT06551142 | A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)(PanTumor-101) | recruiting | Phase 1 | 845 | GlaxoSmithKlineINDUSTRY | 13 | May 22, 2026 | clinicaltrials |
| NCT06686394 | Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | recruiting | Phase 1 / Phase 2 | 81 | Merck Sharp & Dohme LLCINDUSTRY | 6 | May 22, 2026 | clinicaltrials |
| NCT07591857 | The Computerized Retraining and Functional Treatment - Group Intervention(CRAFT-G) | recruiting | N/A | 48 | Hadassah Medical OrganizationOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05402696 | St. Paul's Advanced Resection Center Cohort for Colorectal Neoplasia (SPARC-C)(SPARC-C) | recruiting | — | 3,500 | University of British ColumbiaOTHER | 3 | May 15, 2026 | clinicaltrials |
| NCT07038785 | Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs(PINK) | recruiting | — | 1,204 | SpotitEarlyINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
| NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | recruiting | Phase 2 / Phase 3 | 740 | Eikon TherapeuticsINDUSTRY | 24 | May 8, 2026 | clinicaltrials |
| NCT04043494 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma(LBL 2018) | recruiting | Phase 3 | 683 | University Hospital MuensterOTHER | 21 | May 6, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT07085676 | Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases | recruiting | Phase 1 | 120 | Polina StepenskyOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07361224 | Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion. | recruiting | Phase 1 | 12 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | May 1, 2026 | clinicaltrials |
| NCT04940780 | Integrative Oncology for Patient Symptoms | recruiting | N/A | 750 | Shaare Zedek Medical CenterOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07367750 | Testing the Feasibility of a Self-Management Support Program for Patient With Chronic Diseases in Israel(CDSMP-IL) | recruiting | N/A | 45 | University of HaifaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials